Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
The Guenther Dermatology Research Centre Biogen Idec |
---|---|
Information provided by: | The Guenther Dermatology Research Centre |
ClinicalTrials.gov Identifier: | NCT00301002 |
The purpose of this study is to determine if Alefacept is effective in the treatment of palmar plantar pustulosis.
Condition | Intervention | Phase |
---|---|---|
Psoriasis Palmoplantaris Pustulosis Pustular Psoriasis of Palms and Soles Pustulosis Palmaris et Plantaris Pustulosis of Palms and Soles |
Drug: Alefacept |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Pilot Open-Label Study to Evaluate the Safety and Observe the Effectiveness of 16 Weeks of Alefacept in Palmar Plantar Pustulosis (IST 92) |
Estimated Enrollment: | 15 |
Study Start Date: | June 2005 |
Estimated Study Completion Date: | October 2006 |
Palmar plantar pustulosis is a chronic, disabling skin condition which is difficult to treat since it is often recalcitrant to current treatments and associated with high recurrence rates. This condition appears to be a T lymphocyte mediated condition and is thought by some to be a subtype of psoriasis. Alefacept affects T cell activation and induces apoptosis of memory T cells. It has been shown to be efficacious in the treatment of psoriasis vulgaris and may be associated with prolonged remissions. There is extremely limited experience with use of Alefacept in Palmar Plantar Pustulosis. This pilot trial should provide additional information concerning its use for this indication.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |
The Guenther Dermatology Research Centre | |
London, Ontario, Canada, N6A 3H7 |
Principal Investigator: | Lyn C Guenther, MD, FRCPC | The Guenther Dermatology Research Centre |
Study ID Numbers: | IST 92 |
Study First Received: | March 8, 2006 |
Last Updated: | November 21, 2006 |
ClinicalTrials.gov Identifier: | NCT00301002 |
Health Authority: | Canada: Health Canada |
safety effectiveness Alefacept |
Palmar Plantar Pustulosis |
Alefacept Skin Diseases Psoriasis Skin Diseases, Papulosquamous |
Therapeutic Uses Dermatologic Agents Pharmacologic Actions |